Replies to post #261554 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Another note to highlight is that Merck has been losing income from generic competition with temodar. If Merck can instead use an (potentially) eight year protected product in GBM like DCVAx-l with or without temodar or Keytruda, it can essentially outcompete the temodar generics by simply dropping the price on Temodar, while maintaining profit via DCVAx-l, or whatever they might call it if they acquire it, and ultimately, in some instances, not using temodar at all.